Inhaled Dry Powder Combinations For Pulmonary Fibrosis
What we do
eSpraye is building a portfolio of proprietary dry-powder inhaled therapies for pulmonary fibrosis and interstitial lung disease. Our SPRAYE™ platform is designed to deliver complementary mechanisms directly to the deep lung from a pocket-sized disposable inhaler.
Why eSpraye
1
A platform, not a single assetAn engineered-particle architecture that combines validated and emerging pulmonary mechanisms in practical fixed-dose inhaled regimens.
2
Clear clinical logicSystemic combinations can be limited by toxicity, tolerability and adherence. Local lung delivery is intended to reduce systemic exposure and may make combinations possible that are hard to sustain orally.
3
ConvenienceThe goal is two active ingredients in a single puff from a disposable inhaler, avoiding stacked nebulizations and devices that need power, cleaning and sterilization.
4
Several ways to work togetherLicense or co-develop a combination, apply SPRAYE™ to a third-party pulmonary asset, or build a broader collaboration.